Skip to content

Contact +44 (0) 20 7060 7474 email us

Sales & Marketing

Business Trends: Pharmaceutical Technology

Understanding your Pharmaceutical Customer (Customer Focus)

Publication Date December 2007
Publisher Datamonitor
Product Type Report
Pages 65
ISBN Number not applicable
Product Code DAT01219

Price

£1,185.00
approximately: $1,794 | €1,323

pdf

Buy Now

print £1,220 ($1,847 | €1,362)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, the UK, France, Germany, and India. It is based on the results of Datamonitor's Business Trends primary research, conducted in Q3 and Q4 2007, with a total of 150 life science companies.

Scope

  • In-depth interviews with 150 pharmaceutical and biotechnology companies
  • Geographic coverage includes: the US, the UK, France, Germany, and India
  • The study focuses on the business challenges, IT budget outlook, and the degree to which the market has adopted EDC and SOA solutions
  • Respondents included IT decision-makers such as CIOs and CTOs

Highlights

IT vendors targeting the life science market must demonstrate deep industry knowledge and have high expertise in their specialty product.

Companies in the life science industry must build and maintain their product pipeline to compete with generic drug manufacturers. To achieve this, companies are beginning to change their business models, albeit slow, and are investing more money into technology solutions.

Pharmaceutical and biotechnology companies have several goals that affect their IT strategies, including achieving or maintaining regulatory compliance, raising efficiency, and aligning IT with overall business objectives.

Reasons to Purchase

  • Validate your market messaging and positioning in the life science industry
  • Compare pharmaceutical and biotechnology IT purchasing plans across geographies
  • Identify emerging areas of concern for pharmaceutical and biotechnology companies

Contents